Last reviewed · How we verify
EXPAREL 40 mL
Exparel 40 mL, marketed by Pacira Pharmaceuticals, is a leading local anesthetic used in surgical procedures, maintaining a strong presence in the post-operative pain management segment. Its key strength lies in the extended duration of action, which differentiates it from traditional local anesthetics and supports its widespread adoption. The primary risk to Exparel's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | EXPAREL 40 mL |
|---|---|
| Also known as | bupivacaine liposome injectable suspension |
| Sponsor | Pacira Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Addition of Steroids on Duration of Analgesia (EARLY_PHASE1)
- A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction (PHASE4)
- Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1 (NA)
- Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy (PHASE4)
- Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study (PHASE2)
- Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2 (PHASE2)
- Stopping Opioid Overuse in Obstetrics to Halt Exposure Trial (PHASE4)
- Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXPAREL 40 mL CI brief — competitive landscape report
- EXPAREL 40 mL updates RSS · CI watch RSS
- Pacira Pharmaceuticals, Inc portfolio CI